Skip to main content
SpringerLink
Log in

Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The biokinetics and dosimetry of 111In-DOTA-NOC-ATE (NOCATE), a high-affinity ligand of SSTR-2 and SSTR-5, and 111In-DTPA-octreotide (Octreoscan™, OCTREO) were compared in the same patients.

Methods

Seventeen patients (10 men, 7 women; mean age 60 years), referred for an OCTREO scan for imaging of a neuroendocrine tumour (15), thymoma (1) or medullary thyroid carcinoma (1), agreed to undergo a second study with NOCATE. Whole-body anterior–posterior scans were recorded 0.5 (100 % reference scan), 4, 24 and 48 h (17 patients) and 120 h (5 patients) after injection. In 16 patients the OCTREO scan (178 ± 15 MBq) was performed 16 ± 5 days before the NOCATE scan (108 ± 14 MBq) with identical timing; 1 patient had the NOCATE scan before the OCTREO scan. Blood samples were obtained from 14 patients 5 min to 48 h after injection. Activities expressed as percent of the initial (reference) activity in the whole body, lung, kidney, liver, spleen and blood were fitted to biexponential or single exponential functions. Dosimetry was performed using OLINDA/EXM.

Results

Initial whole-body, lung and kidney activities were similar, but retention of NOCATE was higher than that of OCTREO. Liver and spleen uptakes of NOCATE were higher from the start (p < 0.001) and remained so over time. Whole-body activity showed similar α and β half-lives, but the β fraction of NOCATE was double that of OCTREO. Blood T 1/2β for NOCATE was longer (19 vs. 6 h). As a result, the effective dose of NOCATE (105 μSv/MBq) exceeded that of OCTREO (52 μSv/MBq), and the latter result was similar to the ICRP 106 value of 54 μSv/MBq. Differential activity measurement in blood cells and plasma showed an average of <5 % of NOCATE and OCTREO attached to globular blood components.

Conclusion

NOCATE showed a slower clearance from normal tissues and its effective dose was roughly double that of OCTREO.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Reubi JC, Perrin MH, Rivier JE, Vale W. High affinity binding sites for a somatostatin-28 analog in rat brain. Life Sci. 1981;28:2191–8.

    Article  PubMed  CAS  Google Scholar 

  2. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98.

    Article  PubMed  CAS  Google Scholar 

  3. Ginj M, Chen J, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogs of octreotide for targeted radiotherapy. Eur J Nucl Med Mol Imaging. 2003;30:S198–9.

    Google Scholar 

  4. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836–46.

    Article  PubMed  CAS  Google Scholar 

  5. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res. 2005;11:1136–45.

    PubMed  CAS  Google Scholar 

  6. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.

    PubMed  Google Scholar 

  7. Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med. 2004;45:1725–33.

    PubMed  Google Scholar 

  8. Meyer SL. Data analysis for scientists and engineers. New York: Wiley; 1975. ISBN: 0-471-59995-6.

    Google Scholar 

  9. ICRP. Radiation dose to patients from radiopharmaceuticals – addendum 3 to ICRP publication 53. ICRP publication 106. Ann ICRP. 38(1-2)

  10. Stabin MG, Kooij PP, Bakker WH, Inoue T, Endo K, Coveney J, et al. Radiation dosimetry for indium-111-pentetreotide. J Nucl Med. 1997;38:1919–22.

    PubMed  CAS  Google Scholar 

  11. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The support of the National Foundation for Scientific Research is gratefully acknowledged. The clinical study was performed upon the commitment of the departments of nuclear medicine of the Lausanne and Geneva University Hospitals.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Lausanne University Hospital, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland

    Ariane Boubaker, John O. Prior, Melanie Champendal, Angelika Bischof Delaloye & Franz Buchegger

  2. Department of Nuclear Medicine, University Hospital of Geneva, Geneva 14, Switzerland

    Jean-Pierre Willi & Franz Buchegger

  3. Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland

    Marek Kosinski & Sébastien Baechler

  4. Department of Nuclear Medicine, University Hospital of Freiburg, Freiburg, Germany

    Helmut R. Maecke

  5. Joint Department of Medical Imaging, University Health Network, Toronto, ON, Canada

    Mihaela Ginj

Authors
  1. Ariane Boubaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John O. Prior
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Pierre Willi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melanie Champendal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marek Kosinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Angelika Bischof Delaloye
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Helmut R. Maecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mihaela Ginj
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sébastien Baechler
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Franz Buchegger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franz Buchegger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boubaker, A., Prior, J.O., Willi, JP. et al. Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide. Eur J Nucl Med Mol Imaging 39, 1868–1875 (2012). https://doi.org/10.1007/s00259-012-2210-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-012-2210-0

Keywords

Search

Navigation